[{"id":"f7b6022b-77ea-42fa-ac80-1a76333093f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03926624","created_at":"2021-01-18T19:20:53.790Z","updated_at":"2024-07-02T16:36:02.107Z","phase":"Phase 3","brief_title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","source_id_and_acronym":"NCT03926624","lead_sponsor":"Delta-Fly Pharma, Inc.","biomarkers":" IDH1 • BCL2","pipe":"","alterations":" ","tags":["IDH1 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • decitabine • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • radgocitabine (DFP-10917)"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 11/22/2019","start_date":" 11/22/2019","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-10-20"}]